Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

Authors: Nathalie Rochet, Rachel S Kahn, Andrzej Niemierko, Thomas F Delaney, Anthony H Russell

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Background

To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for advanced endometrial cancer.

Methods

We conducted a retrospective analysis of patients treated at our institution from 2000 to 2011. Inclusion criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine abdomen-confined disease, treated with WAI as part of multimodal therapy. Endpoints were feasibility, acute toxicity, late effects, recurrence-free survival (RFS) and overall survival (OS). Twenty patients were identified. Chemotherapy consisted of 3 to 6 cycles of a platinum-paclitaxel regimen in 18 patients. WAI was delivered using conventional technique to a median total dose of 27.5 Gy.

Results

No grade 4 toxicities occurred during chemotherapy or radiotherapy. No radiation dose reduction was necessary. Three patients developed small bowel obstruction, all in the context of recurrent intraperitoneal disease. Kaplan-Meier estimates and 95% confidence intervals for RFS and OS at one year were 63% (38–80%) and 83% (56-94%) and at 3 years 57% (33-76%) and 62% (34-81%), respectively. On univariate Cox analysis, stage IVB and serous papillary (SP) histology were found to be statistically significantly (at the p = 0.05 level) associated with worse RFS and OS. The peritoneal cavity was the most frequent site of initial failure.

Conclusions

Consolidative WAI following chemotherapy is feasible and can be performed without interruption with manageable acute and late toxicity. Patients with endometrioid adenocarcinoma, especially stage FIGO III, had favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in selected patients. Patients with SP do poorly and do not routinely benefit from this approach.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10-29. 10.3322/caac.20138CrossRefPubMed
2.
Ueda SM, Kapp DS, Cheung MK, et al.: Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008, 198: 218-6.PubMed
3.
Goff BA, Goodman A, Muntz HG, et al.: Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994, 52: 237-240. 10.1006/gyno.1994.1038CrossRefPubMed
4.
Onda T, Yoshikawa H, Mizutani K, et al.: Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997, 75: 836-1841.CrossRef
5.
Randall ME, Filiaci VL, Muss H, et al.: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2006, 4: 36-44.CrossRef
6.
Smith RS, Kapp DS, Chen Q, et al.: Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys 2000, 48: 767-778. 10.1016/S0360-3016(00)00724-0CrossRefPubMed
7.
Stewart KD, Martinez AA, Weiner S, et al.: Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. Int J Radiat Oncol Biol Phys 2002, 54: 527-535. 10.1016/S0360-3016(02)02947-4CrossRefPubMed
8.
Sutton G, Axelrod JH, Bundy BN, et al.: Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the gynecologic oncology group. Gynecol Oncol 2006, 100: 349-354. 10.1016/j.ygyno.2005.08.037CrossRefPubMed
9.
Dusenbery KE, Potish RA, Gold DG, et al.: Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecol Oncol 2005, 96: 635-642. 10.1016/j.ygyno.2004.11.048CrossRefPubMed
10.
Lee SW, Russell AH, Kinney WK: Whole abdomen radiotherapy for patients with peritoneal dissemination of endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys 2003, 56: 788-792. 10.1016/S0360-3016(03)00066-XCrossRefPubMed
11.
Alvarez SA, Havrilesky LJ, Bae-Jump V, et al.: The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007, 107: 285-291. 10.1016/j.ygyno.2007.06.014CrossRef
12.
Bruzzone M, Miglietta L, Franzone P, et al.: Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 2004, 93: 345-352. 10.1016/j.ygyno.2004.02.008CrossRefPubMed
13.
Geller MA, Ivy JJ, Ghebre R, et al.: A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011, 121: 112-117. 10.1016/j.ygyno.2010.12.338CrossRefPubMed
14.
Secord AA, Havrilesky LJ, O’Malley DM, et al.: A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009, 114: 442-447. 10.1016/j.ygyno.2009.06.005CrossRefPubMed
15.
Dinniwell R, Lock M, Pintilie M, et al.: Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys 2005, 62: 104-110. 10.1016/j.ijrobp.2004.09.010CrossRefPubMed
16.
Fyles AW, Dembo AJ, Bush RS, et al.: Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1992, 22: 847-851. 10.1016/0360-3016(92)90778-GCrossRefPubMed
17.
Pickel H, Lahousen M, Petru E, et al.: Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999, 72: 215-219. 10.1006/gyno.1998.5184CrossRefPubMed
18.
Sorbe B: Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003, 13: 278-286. 10.1046/j.1525-1438.2003.13193.xCrossRefPubMed
19.
Whelan TJ, Dembo AJ, Bush RS, et al.: Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys 1992, 22: 853-858. 10.1016/0360-3016(92)90779-HCrossRefPubMed
20.
Fowler JM, Brady WE, Grigsby PW, et al.: Sequential chemotherapy and irradiation in advanced stage endometrial cancer: a gynecologic oncology group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol 2009, 112: 553-557. 10.1016/j.ygyno.2008.11.026CrossRefPubMed
21.
Reisinger SA, Asbury R, Liao SY, et al.: A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a gynecologic oncology group pilot study. Gynecol Oncol 1996, 63: 299-303. 10.1006/gyno.1996.0326CrossRefPubMed
22.
Soper JT, Reisinger SA, Ashbury R, et al.: Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a gynecologic oncology group trial. Gynecol Oncol 2004, 95: 95-100. 10.1016/j.ygyno.2004.06.041CrossRefPubMed
23.
Rochet N, Sterzing F, Jensen A, et al.: Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol 2008, 184: 145-149. 10.1007/s00066-008-1772-zCrossRefPubMed
24.
Rochet N, Sterzing F, Jensen AD, et al.: Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys 2010, 76: 1382-1389. 10.1016/j.ijrobp.2009.03.061CrossRefPubMed
25.
Haie-Meder C, Mazeron R, Magne N: Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol 2010, 96: 351-355. 10.1016/j.radonc.2010.07.010CrossRefPubMed
Metadata
Title
Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes
Authors
Nathalie Rochet
Rachel S Kahn
Andrzej Niemierko
Thomas F Delaney
Anthony H Russell
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-236

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

The benefit of whole brain reirradiation in patients with multiple brain metastases

Research

Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma

Research

Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases – the first Australian experience

Research

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer

Research

Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma

Research

XRCC1 codon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients